PARP inhibitors for maintenance therapy in ovarian cancer will be the No. 9 most influential medical innovation for 2020, predict experts at Cleveland Clinic.
What research abstracts presented at this year’s American Society of Clinical Oncology annual meeting will have the biggest potential impact on clinical practice? Cleveland Clinic Cancer Center physicians make their picks.
With his new, five-year, $1.8 million award, Dr. Gong hopes to improve PARPi therapy by better understanding the mechanisms of resistance.
The data are promising regarding PARP inhibitors, especially in recurrent ovarian cancer. Gynecologic oncologists are awaiting results of current trials in patients with newly diagnosed ovarian cancer as part of primary therapy.